PH12021551262A1 - Macrocyclic compound and use thereof - Google Patents
Macrocyclic compound and use thereofInfo
- Publication number
- PH12021551262A1 PH12021551262A1 PH12021551262A PH12021551262A PH12021551262A1 PH 12021551262 A1 PH12021551262 A1 PH 12021551262A1 PH 12021551262 A PH12021551262 A PH 12021551262A PH 12021551262 A PH12021551262 A PH 12021551262A PH 12021551262 A1 PH12021551262 A1 PH 12021551262A1
- Authority
- PH
- Philippines
- Prior art keywords
- disease
- kidney
- mitochondrial
- inflammatory
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018228234 | 2018-12-05 | ||
| PCT/JP2019/048593 WO2020116660A1 (en) | 2018-12-05 | 2019-12-04 | Macrocyclic compound and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021551262A1 true PH12021551262A1 (en) | 2021-10-25 |
Family
ID=70975488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021551262A PH12021551262A1 (en) | 2018-12-05 | 2021-05-31 | Macrocyclic compound and use thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11518763B2 (https=) |
| EP (1) | EP3890738A4 (https=) |
| JP (2) | JP2022510736A (https=) |
| KR (1) | KR102919982B1 (https=) |
| CN (1) | CN113164468A (https=) |
| AR (1) | AR117251A1 (https=) |
| AU (1) | AU2019391942B2 (https=) |
| BR (1) | BR112021010704A2 (https=) |
| CA (1) | CA3121952C (https=) |
| CL (1) | CL2021001451A1 (https=) |
| CO (1) | CO2021007304A2 (https=) |
| MX (1) | MX2021006527A (https=) |
| NZ (1) | NZ776102A (https=) |
| PH (1) | PH12021551262A1 (https=) |
| SG (1) | SG11202105125XA (https=) |
| TW (1) | TWI820266B (https=) |
| UA (1) | UA127872C2 (https=) |
| WO (1) | WO2020116660A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3833662B1 (en) | 2018-08-20 | 2024-01-17 | Janssen Pharmaceutica NV | Inhibitors of keap1-nrf2 protein-protein interaction |
| AU2020283361B2 (en) | 2019-05-31 | 2025-11-27 | Ube Corporation | Benzotriazole derivative |
| CN116406364A (zh) * | 2020-09-14 | 2023-07-07 | 赛诺菲公司 | 用于治疗红细胞障碍和炎性疾病的四氢异喹啉衍生物 |
| KR20260005897A (ko) * | 2023-04-03 | 2026-01-12 | 에이스링크 테라퓨틱스, 인코포레이티드 | 신규 화합물 및 이의 용도 |
| CN119707895B (zh) * | 2023-12-18 | 2026-03-31 | 江苏苏中药业研究院有限公司 | 一种7-甲酰基-2,3-二氢苯并呋喃-4-碳腈的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012028959A1 (en) | 2010-08-31 | 2012-03-08 | Pablo Villoslada | Agonists of neurotrophin receptors and their use as medicaments |
| DK3492455T3 (da) | 2013-06-21 | 2023-08-14 | Karyopharm Therapeutics Inc | 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer |
| SG11201604611SA (en) * | 2013-12-18 | 2016-07-28 | Glaxosmithkline Ip Dev Ltd | Nrf2 regulators |
| LT3307739T (lt) | 2015-06-15 | 2021-03-10 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 reguliatoriai |
| WO2016203401A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| CA2988373A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| US10201531B2 (en) | 2015-08-12 | 2019-02-12 | Mochida Pharmaceutical Co., Ltd. | Indazolyl-oxo-isothiazole compounds |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| US10351530B2 (en) | 2015-10-06 | 2019-07-16 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as NRF2 regulators |
| JP2020500919A (ja) | 2016-12-12 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしての３−カルボン酸ピロール |
| JP2020500918A (ja) | 2016-12-12 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのｎ−アリールピラゾール |
| EP3555068B1 (en) | 2016-12-14 | 2020-12-02 | GlaxoSmithKline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
| ES2901617T3 (es) | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
| US11117905B2 (en) | 2016-12-14 | 2021-09-14 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as NRF2 activators |
| CA3044773A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activators |
| JP2020502152A (ja) | 2016-12-15 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２アクチベーターとしてのエーテル結合トリアゾール |
| UY37551A (es) | 2016-12-27 | 2018-07-31 | Biogen Ma Inc | Activador de nrf2 |
| WO2018140876A1 (en) * | 2017-01-30 | 2018-08-02 | Biogen Ma Inc. | Nrf2 activator |
| US20190389830A1 (en) | 2017-01-30 | 2019-12-26 | Biogen Ma Inc. | Nrf2 activator |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
-
2019
- 2019-12-04 MX MX2021006527A patent/MX2021006527A/es unknown
- 2019-12-04 AU AU2019391942A patent/AU2019391942B2/en active Active
- 2019-12-04 UA UAA202102856A patent/UA127872C2/uk unknown
- 2019-12-04 NZ NZ776102A patent/NZ776102A/en unknown
- 2019-12-04 BR BR112021010704-5A patent/BR112021010704A2/pt unknown
- 2019-12-04 EP EP19892751.9A patent/EP3890738A4/en active Pending
- 2019-12-04 SG SG11202105125XA patent/SG11202105125XA/en unknown
- 2019-12-04 JP JP2021554804A patent/JP2022510736A/ja active Pending
- 2019-12-04 CN CN201980080214.5A patent/CN113164468A/zh active Pending
- 2019-12-04 US US17/299,659 patent/US11518763B2/en active Active
- 2019-12-04 TW TW108144324A patent/TWI820266B/zh active
- 2019-12-04 AR ARP190103549A patent/AR117251A1/es unknown
- 2019-12-04 CA CA3121952A patent/CA3121952C/en active Active
- 2019-12-04 WO PCT/JP2019/048593 patent/WO2020116660A1/en not_active Ceased
- 2019-12-04 KR KR1020217020790A patent/KR102919982B1/ko active Active
-
2021
- 2021-05-31 PH PH12021551262A patent/PH12021551262A1/en unknown
- 2021-06-02 CL CL2021001451A patent/CL2021001451A1/es unknown
- 2021-06-03 CO CONC2021/0007304A patent/CO2021007304A2/es unknown
-
2024
- 2024-06-25 JP JP2024102161A patent/JP2024123202A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3890738A4 (en) | 2022-08-17 |
| SG11202105125XA (en) | 2021-06-29 |
| US20220119391A1 (en) | 2022-04-21 |
| CA3121952C (en) | 2025-05-13 |
| TWI820266B (zh) | 2023-11-01 |
| WO2020116660A1 (en) | 2020-06-11 |
| AU2019391942A1 (en) | 2021-06-03 |
| CO2021007304A2 (es) | 2021-06-21 |
| TW202039494A (zh) | 2020-11-01 |
| JP2024123202A (ja) | 2024-09-10 |
| NZ776102A (en) | 2024-12-20 |
| CN113164468A (zh) | 2021-07-23 |
| JP2022510736A (ja) | 2022-01-27 |
| MX2021006527A (es) | 2021-07-21 |
| AR117251A1 (es) | 2021-07-21 |
| AU2019391942B2 (en) | 2024-03-21 |
| CL2021001451A1 (es) | 2021-12-24 |
| UA127872C2 (uk) | 2024-01-31 |
| BR112021010704A2 (pt) | 2021-08-24 |
| KR20210099622A (ko) | 2021-08-12 |
| KR102919982B1 (ko) | 2026-02-02 |
| CA3121952A1 (en) | 2020-06-11 |
| US11518763B2 (en) | 2022-12-06 |
| EP3890738A1 (en) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551262A1 (en) | Macrocyclic compound and use thereof | |
| CY1118574T1 (el) | Ενωσεις υποκατεστημενου πυριδινο-2-καρβοξαμιδιου ως αναστολεις κινασης ρυθμισης σηματος αποπτωσης | |
| CR20210085A (es) | Compuestos de 2,6-diaminopiridina | |
| MX365986B (es) | Derivativos de piperidina fusionados con espiro para usarse como inhibidores del canal de potasio medular externo renal. | |
| PH12015502012A1 (en) | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | |
| MX2012015105A (es) | Inhibidores de cinasa de regulacion mediante señal de apoptosis. | |
| SG10201902370QA (en) | Compositions and methods of use of phorbol esters | |
| MD20160069A2 (ro) | Inhibitor al kinazei inductoare de apoptoză | |
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| MX337396B (es) | Metodo para el tratamiento de enfermedades del riñon poliquisticas con derivados de ceramica. | |
| JOP20210329A1 (ar) | مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز | |
| PH12018500261B1 (en) | Azole benzene derivative | |
| GEP20207095B (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| JOP20180029A1 (ar) | مركب حلقي غير متجانس | |
| AU2012358475A8 (en) | An inhalable medicament comprising tiotropium | |
| SA515360085B1 (ar) | مشتق ودواء بيريدين | |
| PH12015502203A1 (en) | Phenyl derivative | |
| NZ712680A (en) | Pyrazole derivative | |
| MX2022004744A (es) | Composiciones que comprenden 2'-fucosil-lactosa para prevenir el asma. | |
| MX2014005165A (es) | Proceso novedoso para la preparacion de acilguanidinas y aciltioureas. | |
| WO2014176510A3 (en) | N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino) naphthalen-1(4h)-ylidene)-n-methylmethanaminium, derivatives, and their use in treating cancer | |
| Levina et al. | Risk factors of development of endothelium dysfunctions at smokers | |
| Bouyssou et al. | Late asthmatic response is modulated by TRPA1 antagonists in ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs | |
| Paralija et al. | Clinical features of pulmonary tuberculosis in patients with diabetes mellitus | |
| Rajaram et al. | C71 CRYSTAL BALL: CLINICAL FEATURES OF PULMONARY VASCULAR DISEASE II: A Survey Of Treatment And Listing Patterns Of Patients With Pulmonary Hypertension For Liver Transplantation |